The Peanut Allergy drugs in development market research report provides comprehensive information on the therapeutics under development for Peanut Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Peanut Allergy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued products.
GlobalData tracks 34 drugs in development for Peanut Allergy by 33 companies/universities/institutes. The top development phase for Peanut Allergy is preclinical with 17 drugs in that stage. The Peanut Allergy pipeline has 29 drugs in development by companies and five by universities/ institutes. Some of the companies in the Peanut Allergy pipeline products market are: National Jewish Health, Scripps Research Institute and AstraZeneca.
The key targets in the Peanut Allergy pipeline products market include Tyrosine Protein Kinase BTK, Toll Like Receptor Family, and Thymic Stromal Lymphopoietin.
The key mechanisms of action in the Peanut Allergy pipeline product include Tyrosine Protein Kinase BTK Inhibitor with two drugs in Phase II. The Peanut Allergy pipeline products include nine routes of administration with the top ROA being Oral and nine key molecule types in the Peanut Allergy pipeline products market including Allergenics (Allergen), and Vaccine.
Peanut Allergy overview
Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions such as hives, redness or swelling; itching or tingling in or around the mouth and throat; digestive problems, such as diarrhea, stomach cramps, nausea or vomiting; tightening of the throat; shortness of breath; or wheezing and runny nose.
For a complete picture of Peanut Allergy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
